Edition:
India

Restorbio Inc (TORC.OQ)

TORC.OQ on NASDAQ Stock Exchange Global Select Market

8.77USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$8.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$21.09
52-wk Low
$7.62

Summary

Name Age Since Current Position

Chen Schor

44 President, Chief Executive Officer, Co-Founder, Director

Joan Mannick

Co-Founder, Chief Medical Officer & Director

John McCabe

Vice President - Finance

Sarb Shergill

Vice President - Clinical Operations

Susan Stewart

Head of Regulatory Affairs

Biographies

Name Description

Chen Schor

Mr. Chen Schor is President, Chief Executive Officer, Co-Founder, Director of the Company. Mr. Schor has vast experience leading biotech companies across all stages, from formation, building a team and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Mr. Schor served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and at leadership positions at several emerging private and public companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

Joan Mannick

Dr. Joan Mannick, M.D., is Co-Founder, Chief Medical Officer & Director of the Company. Prior to joining resTORbio, Dr. Mannick was Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research where Dr. Mannick led the clinical program at Novartis that targets pathways regulating aging to treat aging-related conditions. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme, Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program.

John McCabe

Mr. John J. McCabe is Vice President - Finance of the Company. McCabe brings more than 25 years of finance and accounting experience to resTORbio. Prior to joining resTORbio, he was Chief Financial Officer with Eleven Biotherapeutics, Inc., a biologics oncology company focused on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs). Prior to that, Mr. McCabe served as Vice President of Finance at Clinical Data, Inc., a drug developer that was acquired by Forest Laboratories for $1.2 billion after FDA approval of its lead drug product for depression, Viibryd®. Prior to that, Mr. McCabe served in several financial roles at Interleukin Genetics, Inc., a genetics-focused personalized health company. John began his career working for the accounting firm of Coopers & Lybrand LLP, now known as PricewaterhouseCoopers LLP. He received a B.S. in Business Administration from the University of Vermont and is also a Certified Public Accountant.

Sarb Shergill

Dr. Sarb Shergill, Ph.D., is Vice President - Clinical Operations of the Company. Dr. Shergill joins resTORbio from Akebia Therapeutics, where she led global clinical operations, overseeing four large phase III cardiovascular outcomes studies, four Phase II studies (including studies in Japan) and several clinical pharmacology studies, as well as overseeing clinical research organization activities and managing the clinical budget. Prior to joining Akebia Therapeutics in 2015, Dr. Shergill was an Associate Vice President of Clinical Research at Genzyme working in multiple therapeutic areas. During Dr. Shergill’s tenure at Genzyme, she led a global group of senior project leaders and led the clinical operations execution of more than 80 clinical trials (Phase I-IV). Dr. Shergill served as the Genzyme representative for many competent authority (FDA, EMA and MHRA) pre-inspection readiness initiatives as well as for regulatory inspections conducted on Genzyme products. Dr. Shergill also has experience working at a CRO and has investigator site level experience having worked in Canada for an academic teaching center running multiple studies in an ICU and multi-organ transplant setting. Dr. Shergill received her B.Sc. in Pharmacology from the University of Portsmouth, UK and her Ph.D. in Pharmacology from Liverpool John Moores University in the UK.

Susan Stewart

Mrs. Susan Stewart, J.D., is Head of Regulatory Affairs of the Company. Mrs. Stewart brings to resTORbio more than 25 years of regulatory affairs and quality assurance experience in the development and commercialization of pharmaceutical products and devices. Mrs. Stewart served in various leadership roles overseeing regulatory affairs, quality and compliance at Tokai Pharmaceuticals, TransMolecular and Genzyme Corporation. While at Genzyme, Sue was the regulatory lead on novel drug development collaborations with Medtronic, Diacrin, Cambridge Antibody Technologies and Dyax. Mrs. Stewart’s commercial product experience includes global registration and life-cycle management of Renagel®, Synvisc®, Carticel® and Thyrogen®. Sue holds a J.D from Concord Law School and a B.A. from the University of Massachusetts. She is a Fellow of the Regulatory Affairs Professionals Society (FRAPS and is both U.S. and European Union Regulatory Affairs Certified).

Basic Compensation

Name Fiscal Year Total

Chen Schor

--

Joan Mannick

--

John McCabe

--

Sarb Shergill

--

Susan Stewart

--
As Of 

Options Compensation